MedChemExpress LLC (MCE)

MedChemExpress - Model Frexalimab - 2515463-86-0

Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research[1][2][3][4][5].

Frexalimab

MCE China：Frexalimab

Brand：MedChemExpress (MCE)

Cat. No.HY-P99625

CAS：2515463-86-0

Synonyms：SAR441344; INX-021

Purity：99.00%

Storage：Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping：Shipping with dry ice.

Description：Frexalimab (SAR441344) is a second-generation monoclonal antibody targeting the CD40 ligand (CD40L) with a good safety profile. Frexalimab inhibits the binding between CD40 and CD40L to modulate immune response. Frexalimab is likely to help prevent the process of β-cell destruction. Frexalimab is proming for multiple sclerosis, lupus erythematosus, Sjögren’s syndrome and type I diabetes research.

In Vitro：Frexalimab is a second-generation anti-CD40L humanized IgG1 monoclonal antibody that has been Fc-engineered. The Fc engineering abrogates the platelet activation that is triggered by FcγRIIa stimulation by immune complexes[2].

Species：Chimeric

Isotype：Human IgG1 kappa

Recommend Isotype Controls：Human IgG1 kappa, Isotype Control

References：

[1]. Bruce A C Cree, et al. New drugs for multiple sclerosis: new treatment algorithms. Curr Opin Neurol. 2022 Jun 1;35(3):262-270. [Content Brief]

[2]. Vermersch P, et al. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. N Engl J Med. 2024 Feb 15;390(7):589-600. [Content Brief]

[3]. Carvalho T. Anti-CD40L antibody frexalimab slows new brain lesions in multiple sclerosis. Nat Med. 2023 Aug;29(8):1882-1883. [Content Brief]

[4]. Weiskorn J, et al. Moving from Insulin Substitution to the Treatment of the Underlying Autoimmune Disease in Type 1 Diabetes. Horm Res Paediatr. 2024 Apr 30:1-8. [Content Brief]

[5]. Maddaloni E, et al. Immune checkpoint modulators in early clinical development for the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2024 Apr;33(4):303-318. [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。